Johnson & Johnson

What you need to know about Johnson & Johnson’s 2025 second-quarter earnings

16 Jul 2025

See an infographic breakdown of the company’s second-quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.

The Red Couch on the Road

10 Jul 2025

Follow The Red Couch on the Road, a video series from Johnson & Johnson that reveals the people and ideas reshaping the future of care.

Introducing the first and only daily disposable multifocal contact lens for people with astigmatism

25 Jun 2025

Discover Acuvue® Oasys Max 1-Day, the first daily multifocal toric contact lens for astigmatism—clear vision, comfort and blue light filtering.

J&J CareCommunity | Empowering nurses & health workers worldwide

18 Jun 2025

J&J CareCommunity is Johnson & Johnson’s global social impact platform supporting nurses and community health workers to expand access to quality care in underserved communities around the world.

Five health workers who are changing care: How J&J is championing nurses and community health workers

18 Jun 2025

Discover how J&J CareCommunity supports nurses and community health workers worldwide, highlighting five individuals making significant strides in improving healthcare access and outcomes.

The future of knee replacement surgery

18 Jun 2025

Innovative implants and robotic-assisted surgery techniques are reducing post-op recovery time and helping patients get back to living their lives.

What roles do PFA and RFA play in the treatment of AFib?

18 Jun 2025

Both are types of cardiac ablation—but are distinct in a few key ways. Read more.

Johnson & Johnson’s dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

13 Jun 2025

Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease 75-80% complete response rate

New results for Johnson & Johnson’s bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia

12 Jun 2025

Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for the treatment of relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML Pha

Significant efficacy benefit of IMBRUVICA

12 Jun 2025

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free

View details about the software product Informachine News Trackers